These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 26908764)

  • 21. Solid Organ Transplantation.
    Bal S; Landau HJ
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1161-1175. PubMed ID: 33099431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis.
    Oke O; Sethi T; Goodman S; Phillips S; Decker I; Rubinstein S; Concepcion B; Horst S; Jagasia M; Kassim A; Harrell SL; Langone A; Lenihan D; Rawling KT; Slosky D; Cornell RF
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1473-1477. PubMed ID: 28546074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiac amyloidosis secondary to multiple myeloma: successful sequential cardiac and autologous stem cell transplantations with excellent outcome.
    Biliński J; Biernacka EK; Januszewicz A
    Eur Heart J; 2021 Sep; 42(36):3803. PubMed ID: 34165537
    [No Abstract]   [Full Text] [Related]  

  • 24. AL amyloidosis in a young adult: remission with autologous stem cell transplantation.
    Golmia RP; Bello IC; Rosseto E; Guerra JC; Mangueira C; Scheinberg MA
    Rev Bras Reumatol; 2010; 50(5):603-8. PubMed ID: 21125195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation.
    Leung N; Dispenzieri A; Lacy MQ; Kumar SK; Hayman SR; Fervenza FC; Cha SS; Gertz MA
    Clin J Am Soc Nephrol; 2007 May; 2(3):440-4. PubMed ID: 17699449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
    Frossard V; Ketterer N; Rosselet A; Meier P; Cairoli A; Duchosal MA; Kovacsovics T
    Ann Hematol; 2009 Jul; 88(7):681-5. PubMed ID: 19066891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease.
    Casserly LF; Fadia A; Sanchorawala V; Seldin DC; Wright DG; Skinner M; Dember LM
    Kidney Int; 2003 Mar; 63(3):1051-7. PubMed ID: 12631087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from all patients treated in 1994-2009.
    Rosengren S; Mellqvist UH; Nahi H; Forsberg K; Lenhoff S; Strömberg O; Ahlberg L; Linder O; Carlson K
    Bone Marrow Transplant; 2016 Dec; 51(12):1569-1572. PubMed ID: 27694943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Long-term Outcomes after VAD plus SCT Therapy in a Patient with AL Amyloidosis and Severe Factor X Deficiency.
    Iwadate D; Hasegawa E; Hoshino J; Hayami N; Sumida K; Yamanouchi M; Sekine A; Kawada M; Hiramatsu R; Suwabe T; Sawa N; Yuasa M; Wake A; Fujii T; Ohashi K; Takaichi K; Ubara Y
    Intern Med; 2018 Mar; 57(5):701-706. PubMed ID: 29093408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement.
    Badar T; Cornelison AM; Shah ND; Bashir Q; Parmar S; Patel K; Hosing C; Popat U; Weber DM; Thomas SK; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH
    Eur J Haematol; 2016 Oct; 97(4):342-7. PubMed ID: 26773409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Therapy options in systemic AL-amyloidosis with renal involvement].
    Hetzel GR; Schneider P; Mondry A; Heering P; Heyll A; Grabensee B
    Dtsch Med Wochenschr; 2000 Aug; 125(34-35):997-1002. PubMed ID: 11004911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose melphalan and autologous stem cell transplantation for systemic light-chain amyloidosis: a single institution retrospective analysis of 40 cases.
    Tsukada N; Ikeda M; Shingaki S; Miyazaki K; Meshitsuka S; Yoshiki Y; Abe Y; Suzuki K
    Int J Hematol; 2016 Mar; 103(3):299-305. PubMed ID: 26703787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation.
    Herrmann SM; Gertz MA; Stegall MD; Dispenzieri A; Cosio FC; Kumar S; Lacy MQ; Dean PG; Prieto M; Zeldenrust SR; Buadi FK; Russell SJ; Nyberg SL; Hayman SR; Dingli D; Fervenza FC; Leung N
    Nephrol Dial Transplant; 2011 Jun; 26(6):2032-6. PubMed ID: 21543655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
    Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
    Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis.
    Cordes S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Kumar SK; Hogan WJ; Gertz MA
    Cancer; 2012 Dec; 118(24):6105-9. PubMed ID: 22707405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autologous stem cell transplantation for AL amyloidosis: a standard therapy?
    Moreau P
    Leukemia; 1999 Dec; 13(12):1929-31. PubMed ID: 10602412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolution of Hematopoietic Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
    Sher T; Dispenzieri A; Gertz MA
    Biol Blood Marrow Transplant; 2016 May; 22(5):796-801. PubMed ID: 26475727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toxic megacolon: a life-threatening complication of high-dose therapy and autologous stem cell transplantation among patients with AL amyloidosis.
    Hayes-Lattin BM; Curtin PT; Fleming WH; Leis JF; Stepan DE; Schubach S; Maziarz RT
    Bone Marrow Transplant; 2002 Sep; 30(5):279-85. PubMed ID: 12209349
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Immunoglobulin light chain amyloidosis: recent molecular, clinical and therapeutic approach].
    Thierry A; Bridoux F; Goodman H; Belmouaz S; Abou Ayache R; Desport E; Jaccard A; Touchard G
    Nephrologie; 2004; 25(4):111-8. PubMed ID: 15291138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modern treatment of amyloidosis: unresolved questions.
    Dember LM
    J Am Soc Nephrol; 2009 Mar; 20(3):469-72. PubMed ID: 19073820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.